methyl O-β-D-galactopyranosyl-(1-4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1-3)-O-β-D-galactopyranosyl-(1-4)-β-D-glucopyranoside | 95795-80-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl O-β-D-galactopyranosyl-(1-4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1-3)-O-β-D-galactopyranosyl-(1-4)-β-D-glucopyranoside
• 英文别名: methyl 4-O-<3-O-(2-acetamido-2-deoxy-4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)-β-D-galactopyranosyl>-β-D-glucopyranoside；Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)b-Glc1Me；N-[(2S,3R,4R,5S,6R)-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide
• CAS: 95795-80-5
• 化学式: C₂₇H₄₇NO₂₁
• 分子量: 721.664
• InChiKey: VCYGUGJYKUBPCQ-ZFAFJDKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.9
• 重原子数：
  49
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  346
• 氢给体数：
  13
• 氢受体数：
  21

反应信息

• 作为产物：
  描述：

  methyl 4-O-<3-O-<2-acetamido-3,6-di-O-acetyl-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl>-β-D-galactopyranosyl>-β-D-glucopyranoside 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以68%的产率得到methyl O-β-D-galactopyranosyl-(1-4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1-3)-O-β-D-galactopyranosyl-(1-4)-β-D-glucopyranoside
  参考文献：
  名称：

  对应于肺炎链球菌识别的受体结构的二糖，三糖和四糖的合成

  摘要：

  摘要描述了甲基2-乙酰氨基-2-脱氧-4-O-β-d-吡喃半乳糖苷-α-d-吡喃葡萄糖苷，甲基2-乙酰氨基-2-脱氧-4- O-β-d-吡喃半乳糖苷-β的合成-d-吡喃葡萄糖苷，甲基3- O-（2-乙酰氨基-2-脱氧-β-d-吡喃葡萄糖基-β-d-吡喃半乳糖苷，甲基3- O-（2-乙酰氨基-2-脱氧-4- O-β -d-吡喃半乳糖基-β-d-吡喃吡喃糖基）-β-d-吡喃半乳糖苷和甲基4-O-[3-O-（2-乙酰氨基-2-脱氧-4-O-β-d-吡喃半乳糖基-β- d-吡喃葡萄糖基）-β-d-吡喃半乳糖基]-β-d-吡喃葡糖苷。

  DOI：

  10.1016/0008-6215(85)85219-8

文献信息

• Protein particles for therapeutic and diagnostic use
  申请人：——

  公开号：US20020142046A1

  公开（公告）日：2002-10-03

  Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.

  通过在颗粒组合物中加入稳定剂，可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外，还公开了交联或非交联的纤维蛋白原涂层微粒，以及它们作为与血小板和自身的共聚物的用途，以达到缩短出血时间和增强凝血酶效果的目的。
• Glycosylation of lactose. Synthesis of methyl O-(2-acetamido-2-deoxy-β-d-glucopyranosyl)-(1→3)-O-β-d-galactopyranosyl-(1→4)-β-d-glucopyranoside and methyl O-β-d-galactopyranosyl-(1→4)-O-(2-acetamido-2-deoxy-β-d-glucopyranosyl)-(1→3)-O-β-d-galactopyranosyl- (1→4)-β-d-glucopyranoside
  作者：Aurelio Maranduba、Alain Veyrières

  DOI：10.1016/s0008-6215(00)90785-7

  日期：1985.1
• Carbohydrate derivatives and compositions thereof for therapeutic or diagnostic use
  申请人：ANDERSSON, Bengt

  公开号：EP0126043B1

  公开（公告）日：1989-10-25
• US5616311A
  申请人：——

  公开号：US5616311A

  公开（公告）日：1997-04-01
• US5725804A
  申请人：——

  公开号：US5725804A

  公开（公告）日：1998-03-10